Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's senior management team will engage in a fireside chat on Tuesday, December 3 at 11:30 a.m. ET in New York.

The event will be accessible via live webcast in the Investor section of Karyopharm's website under 'Events & Presentations,' with replay availability after the event.

NEWTON, Mass., Nov. 25, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Piper Sandler 36^th Annual Healthcare Conference in a fireside chat on Tuesday, December 3 at 11:30 a.m. ET in New York, NY.

A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor section of the Company's website, https://investors.karyopharm.com/events-presentations, and will be available for replay following the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO^® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO^®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-the-piper-sandler-36th-annual-healthcare-conference-302314838.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

When is Karyopharm (KPTI) presenting at the Piper Sandler Healthcare Conference?

Karyopharm will present at the Piper Sandler Healthcare Conference on Tuesday, December 3 at 11:30 a.m. ET in New York.

How can I watch Karyopharm's (KPTI) presentation at the Piper Sandler Conference?

The presentation can be watched via live webcast in the 'Events & Presentations' section of Karyopharm's investor website at investors.karyopharm.com/events-presentations.

What type of presentation will Karyopharm (KPTI) give at the Piper Sandler Conference?

Karyopharm's senior management team will participate in a fireside chat format presentation at the conference.

Will Karyopharm's (KPTI) Piper Sandler Conference presentation be available for replay?

Yes, the presentation will be available for replay on Karyopharm's investor website following the event.